Cytoplasmic and nuclear programmed death ligand 1 expression in peritumoral stromal cells in breast cancer: Prognostic and predictive value

Table 6 Distribution of patients with and without programmed cell death protein 1 ligand 1 expression in the endothelial cells of tumor microvessels, n (%)

Breast cancer characteristics	PDCD1 LG1 expression in endothelial cells of tumor microvessels		P value χ² tests
	Absent	Present
T stage
Т in situ	2 (50.0)	5 (50.0)	0.06
Т1в	4 (36.4)	7 (63.6)
Т1с	57 (64.0)	32 (36.0)
Т2	2 (50.0)	2 (50.0)
N stage
N0	58 (71.6)	23 (28.4)	0.36
N1	27 (57.5)	20 (42.5)
N2	10 (62.5)	6 (37.5)
N3	2 (50.0)	2 (50.0)
Tumor grade
G1	12 (75.0)	4 (25.0)	0.41
G2	56 (61.5)	35 (38.5)
G3	29 (70.7)	12 (29.3)
Lymphovascular invasion
No	59 (70.2)	25 (29.8)	0.16
Yes	38 (59.4)	26 (40.6)
Perineural invasion
No	74 (64.3)	41 (35.7)	0.56
Yes	23 (69.7)	10 (30.3)
ER status
Negative	10 (62.5)	6 (37.5)	0.78
Positive	87 (65.9)	45 (34.1)
PR status
Negative	29 (70.7)	12 (29.3)	0.41
Positive	68 (63.5)	39 (36.5)
HER2 status
HER2 -	87 (68.0)	41 (32.0)	0.11
HER2+	10 (50.0)	10 (50.0)
Molecular biological subtype
Luminal A	38 (67.9)	18 (32.1)	0.13
Luminal B HER2-	46 (69.7)	20 (30.3)
Luminal B HER2+	3 (30.0)	7 (70.0)
Non-luminal HER2+	7 (70.0)	3 (30.0)
TNBC	3 (50.0)	3 (50.0)

ER: Estrogen receptor; HER2: Human epidermal growth factor receptor 2; PR: Progesterone receptor; TNBC: Triple-negative breast cancer.